MedTrace Logo

Study of the Effect of Chondroitin Sulfate on Structural Changes in Knee Osteoarthritis Patients Assessed by MRI

NCT01354145 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 194

Last updated 2016-08-19

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to compare the cartilage volume loss at the Baseline visit and after 24 months of treatment in patients treated with CHONDROITIN SULPHATE (CONDROSAN) 1200 mg daily vs. patients treated with CELECOXIB 200 mg daily.

Conditions

Interventions

DRUG

Chondroitin sulfate

Chondroitin sulphate 1200 mg/day, 24 months treatment period

DRUG

Celecoxib

Celecoxib 200 mg/day, 24 months treatment period

Sponsors & Collaborators

  • Bioiberica

    lead INDUSTRY

Principal Investigators

  • Jean-Pierre Pelletier, MD · Principal Author

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2014-09-30
Completion
2014-10-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01354145 on ClinicalTrials.gov